Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call and Webcast on Tuesday, February 25, 2025, at 8:00 a.m. ET
Fulcrum Therapeutics (FULC), a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases, has scheduled its fourth quarter and full year 2024 financial results release for Tuesday, February 25, 2025, before U.S. market opening.
The company will host a conference call and webcast at 8:00 a.m. ET on the same day, where management will discuss the results and provide updates on corporate developments. Participants can access the call through registration, and an audio webcast will be available through the company's Investor Relations website.
Fulcrum Therapeutics (FULC), un'azienda biofarmaceutica in fase clinica che si concentra sullo sviluppo di piccole molecole per malattie rare definite geneticamente, ha programmato la pubblicazione dei suoi risultati finanziari del quarto trimestre e dell'intero anno 2024 per martedì 25 febbraio 2025, prima dell'apertura del mercato statunitense.
L'azienda ospiterà una conferenza telefonica e un webcast alle 8:00 a.m. ET nello stesso giorno, durante la quale la direzione discuterà i risultati e fornirà aggiornamenti sugli sviluppi aziendali. I partecipanti possono accedere alla chiamata tramite registrazione e un webcast audio sarà disponibile sul sito web delle Relazioni con gli Investitori dell'azienda.
Fulcrum Therapeutics (FULC), una compañía biofarmacéutica en etapa clínica centrada en el desarrollo de pequeñas moléculas para enfermedades raras definidas genéticamente, ha programado la publicación de sus resultados financieros del cuarto trimestre y del año completo 2024 para el martes 25 de febrero de 2025, antes de la apertura del mercado en EE. UU.
La compañía llevará a cabo una conferencia telefónica y un webcast a las 8:00 a.m. ET el mismo día, donde la dirección discutirá los resultados y proporcionará actualizaciones sobre los desarrollos corporativos. Los participantes pueden acceder a la llamada a través de registro, y un webcast de audio estará disponible en el sitio web de Relaciones con Inversores de la compañía.
Fulcrum Therapeutics (FULC), 유전적으로 정의된 희귀 질환을 위한 소분자 개발에 중점을 둔 임상 단계의 생명공학 회사는 2024년 4분기 및 연간 재무 결과 발표를 2025년 2월 25일 화요일 미국 시장 개장 이전에 예정하고 있습니다.
회사는 같은 날 오전 8시 ET에 컨퍼런스 콜 및 웹캐스트를 개최하며, 경영진이 결과를 논의하고 기업 발전에 대한 업데이트를 제공합니다. 참가자는 등록을 통해 통화에 접근할 수 있으며, 회사의 투자자 관계 웹사이트를 통해 오디오 웹캐스트가 제공됩니다.
Fulcrum Therapeutics (FULC), une entreprise biopharmaceutique en phase clinique axée sur le développement de petites molécules pour des maladies rares définies génétiquement, a prévu la publication de ses résultats financiers du quatrième trimestre et de l'année complète 2024 pour mardi 25 février 2025, avant l'ouverture du marché américain.
L'entreprise organisera une conférence téléphonique et un webcast à 8h00 ET le même jour, où la direction discutera des résultats et fournira des mises à jour sur les développements de l'entreprise. Les participants peuvent accéder à l'appel par inscription, et un webcast audio sera disponible sur le site des relations investisseurs de l'entreprise.
Fulcrum Therapeutics (FULC), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung kleiner Moleküle für genetisch definierte seltene Krankheiten konzentriert, hat die Veröffentlichung seiner Finanzergebnisse für das vierte Quartal und das Gesamtjahr 2024 für Dienstag, den 25. Februar 2025, vor der Eröffnung des US-Marktes angesetzt.
Das Unternehmen wird am selben Tag um 8:00 Uhr ET eine Telefonkonferenz und einen Webcast veranstalten, bei der das Management die Ergebnisse diskutiert und Updates zu Unternehmensentwicklungen bereitstellt. Teilnehmer können über eine Registrierung auf den Anruf zugreifen, und ein Audio-Webcast wird auf der Website der Investor Relations des Unternehmens verfügbar sein.
- None.
- None.
CAMBRIDGE, Mass., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that its fourth quarter and full year 2024 financial results will be released on Tuesday, February 25, 2025, before the U.S. financial markets open. Management will host a conference call and webcast at 8:00 a.m. ET to discuss the results and provide an update on recent corporate developments.
Individuals may register for the conference call by clicking the link here. Once registered, participants will receive dial-in details and unique PIN which will allow them to access the call. An audio webcast will be accessible through the Investor Relations section of the company’s website at www.fulcrumtx.com or by clicking here. Following the live webcast, an archived replay will also be available.
About Fulcrum Therapeutics
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s lead program in clinical development is pociredir, a small molecule designed to increase expression of fetal hemoglobin and in development for the treatment of sickle cell disease (SCD). Fulcrum uses proprietary technology to identify drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. For more information, visit www.fulcrumtx.com and follow us on Twitter/X (@FulcrumTx) and LinkedIn.
Contact:
Chris Calabrese
LifeSci Advisors, LLC
ccalabrese@lifesciadvisors.com
917-680-5608
FAQ
When will Fulcrum Therapeutics (FULC) release its Q4 and full year 2024 earnings?
What time is FULC's Q4 2024 earnings call?
How can investors access FULC's Q4 2024 earnings call?
Will FULC's Q4 2024 earnings call webcast be available for replay?
